RRSS #08: Evaluating Prevalence HPV Infection Among Head and Neck Cancer Patients

RRRSS

基本信息

  • 批准号:
    7952659
  • 负责人:
  • 金额:
    $ 13.68万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-08-01 至 2010-07-31
  • 项目状态:
    已结题

项目摘要

Head and neck cancer (HNC) includes malignant tumors arising from a variety of sites in the upper aerodigestive tract (UADT), including the oral cavity, the pharynx, and the larynx. HNC represents the fifth most common malignancy worldwide. It was ranked as the eighth leading cause of cancer death in the world. In 2008, there were an estimated 48,000 new cases and more than 11,000 deaths of HNC in the United States. More than 90% of head and neck malignancies are squamous cell carcinoma (SCC), originating from the epithelium which lines the UADT. The incidence of head and neck squamous cell carcinoma (HNSCC) increases with age and is more common in men than in women. Tobacco and alcohol consumption are well established risk factors for HNSCC. However, a proportion of HNSCC occurs in nonsmokers and nondrinkers, suggesting the presence of other risk factors. Human papilloma virus (HPV) has been proven to be an etiologic factor for cervical cancer. HPV primarily infects the epithelium and induces benign as well as malignant lesions of the mucosa and skin. More than 70 types of HPV have been described. According to their implications in carcinogenesis, particularly the malignant progression of cervical tumors, HPV types were classified into high-risk (16, 18, 31,33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82) and low-risk (6, 11, 26, 40, 42, 53, 54, 55, 57, 66, 83 and 84) groups. Low-risk types are associated with benign lesions such as warts, while infections with high-risk types progress to malignant lesions. High-risk HPV types 16 and 18 have been reported as the most prominent etiologic factors behind the development of cervical cancer. In recent decades, molecular and epidemiologic data have linked HPV with HNSCC. Although HPV type 16 alone was found to account for more than 90% of HPV-positive HNSCC and HPV type 18 is the second most common genotype, a variety of other high- and low-risk HPVs were also found to be present in HNSCC. In fact, the prevalence of other HPV genotypes (other than the 16 and 18) has been significantly underreported, either due to lack of sensitive viral detection methods used, type of specimen tested, and lack of actual testing for these non-HPV16 and non-HPV18 genotypes. Furthermore, the contribution of non-HPV16/18 genotypes as cofactors that participate in the oncogenic process has not been fully examined, nor has it been excluded that different HPV genotypes have different colonization and oncogenic potential in distinct oral tumor sites. Most HPV-associated HNSCC tend to occur in the oropharynx, with highest distribution in the tonsils. The proportion of HNSCC that are potentially HPV-related has been on the rise in the U.S., while the potentially HPV-unrelated HNSCC declined. Presence of HPV in HNSCC has been linked with sexual behaviors. Patients with HPV-positive HNSCC tend to be younger and free of smoking and drinking history, the majority of them are females. They also seem to have a better survival than the HPV-negative HNSCC patients, due to an increased radiocurability of HPV-positive tumors. Evidence supports the idea that HNSCC is a multifactorial disease with at least two, possibly distinct, pathways, one driven by tobacco and alcohol consumption, the other driven by HPV. The reported prevalence of HPV in HNSCC varied between 0-100% . This broad variation in HPV detection rates is attributable to tumor site, HPV detection method (polymerase chain-reaction (PCR), in situ hybridization (ISH), or Southern hybridization), specimen source and collection methods (swabs, brushings, mouthwash, fresh tissue, fixed tissue, etc.), use of HPV type specific vs. universal primers, and sample size and composition. PCR is consider more sensitive than the other testing methods. Small sample size and the inability to classify cases by anatomic subsite and to differentiate primary, recurrent, and metastatic tumors is likely to have contributed to the inconsistencies. The recognition of HPV as a major etiologic agent for HNSCC necessitates a new understanding of the diseases development and stimulates research in order to develop strategies for the screening, education, prevention, diagnosis, and treatment of HNSCC.
头颈癌(HNC)包括发生在上呼吸道消化道(UADT)不同部位的恶性肿瘤,包括口腔、咽部和喉部。HNC是全球第五大最常见的恶性肿瘤。它被列为世界上第八大癌症死亡原因。2008年,美国估计有4.8万例新发HNC病例,1.1万多人死亡。超过90%的头颈部恶性肿瘤是鳞状细胞癌(SCC),起源于UADT的上皮。头颈部鳞状细胞癌(HNSCC)的发病率随着年龄的增长而增加,男性比女性更常见。烟草和酒精消费是HNSCC的公认危险因素。然而,非吸烟者和非饮酒者中也有一定比例的HNSCC,这表明存在其他危险因素。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DENNIS M. DEAPEN其他文献

DENNIS M. DEAPEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DENNIS M. DEAPEN', 18)}}的其他基金

Innovative Infrastructure to Enhance the California Teachers Study
加强加州教师研究的创新基础设施
  • 批准号:
    9342691
  • 财政年份:
    2015
  • 资助金额:
    $ 13.68万
  • 项目类别:
TAS::75 0849::TAS SURVEILLANCE, EPIDEMIOLOGY AND END RESULTS PROGRAM
TAS::75 0849::TAS 监测、流行病学和最终结果计划
  • 批准号:
    8317514
  • 财政年份:
    2011
  • 资助金额:
    $ 13.68万
  • 项目类别:
TAS::75 0849::TAS
塔斯马尼亚州::75 0849::塔斯马尼亚州
  • 批准号:
    8317515
  • 财政年份:
    2011
  • 资助金额:
    $ 13.68万
  • 项目类别:
TAS::75 0849::TAS
塔斯马尼亚州::75 0849::塔斯马尼亚州
  • 批准号:
    8163696
  • 财政年份:
    2010
  • 资助金额:
    $ 13.68万
  • 项目类别:
TAS::75 0849::TAS
塔斯马尼亚州::75 0849::塔斯马尼亚州
  • 批准号:
    8163697
  • 财政年份:
    2010
  • 资助金额:
    $ 13.68万
  • 项目类别:
TAS::75 0849::TAS
塔斯马尼亚州::75 0849::塔斯马尼亚州
  • 批准号:
    8163694
  • 财政年份:
    2010
  • 资助金额:
    $ 13.68万
  • 项目类别:
CORE--CSP Cancer Surveillance
核心--CSP癌症监测
  • 批准号:
    6999269
  • 财政年份:
    2005
  • 资助金额:
    $ 13.68万
  • 项目类别:
SURVEILLANCE , EPIDEMIOLOGY AND END RESULTS (SEER) PROGRAM
监测、流行病学和最终结果 (SEER) 计划
  • 批准号:
    7542314
  • 财政年份:
    2003
  • 资助金额:
    $ 13.68万
  • 项目类别:
RRSS #12 - Patterns of Care - Diagnosis Year 2008
RRRSS
  • 批准号:
    7962662
  • 财政年份:
    2003
  • 资助金额:
    $ 13.68万
  • 项目类别:
Surveillance, Epidemiology and End Results (SEER) - USC
监测、流行病学和最终结果 (SEER) - USC
  • 批准号:
    8065667
  • 财政年份:
    2003
  • 资助金额:
    $ 13.68万
  • 项目类别:

相似国自然基金

一氧化氮供体MN-08在亨廷顿舞蹈病模型清除mHTT和抑制神经炎症的作用及机理研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    15.0 万元
  • 项目类别:
    省市级项目
ZmLBD08-6调控玉米耐旱性功能及育种应用
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
A03和A08染色体上多基因介导的油菜根肿病免疫抗性形成的遗传基础
  • 批准号:
    32372171
  • 批准年份:
    2023
  • 资助金额:
    51 万元
  • 项目类别:
    面上项目
生物炭载解化感物质促生菌Bacillus cereus WL08缓解半夏连作障碍的机制研究
  • 批准号:
    32360023
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
甘蓝型油菜控制脂肪酸组分关键基因BnTRAM-A08的功能验证及调控机理研究
  • 批准号:
    LY23C130007
  • 批准年份:
    2023
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
共享航次计划2022年度海洋地球物理科学考察实验研究(航次编号:NORC2023-08)
  • 批准号:
    42249908
  • 批准年份:
    2022
  • 资助金额:
    380.00 万元
  • 项目类别:
    专项项目
共享航次计划2021年度南海地球物理科学考察实验研究(航次编号:NORC2022-08)
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    400 万元
  • 项目类别:
创新药物MN-08改善毛细血管痉挛和微循环障碍治疗蛛网膜下腔出血的机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
共享航次计划2021年度南海地球物理科学考察实验研究(航次编号:NORC2022-08)
  • 批准号:
    42149908
  • 批准年份:
    2021
  • 资助金额:
    400.00 万元
  • 项目类别:
    专项项目
Rik08在非梗阻性无精子症中的作用及其分子机制
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目

相似海外基金

NIH NATIONAL BRAIN AND TISSUE REPOSITORYPERIOD OF PERFORMANCE: 09/01/2019 - 08/31/2021 (UNCHANGED)TOTAL CONTRACT AMOUNT: $4,937,543.50 (UNCHANGED)TOTAL OBLIGATED AMOUNT: $4,937,543.50 (UNCHANGED)
NIH 国家脑和组织存储库执行期限:2019 年 1 月 9 日 - 2021 年 8 月 31 日(不变)合同总金额:4,937,543.50 美元(不变)总承付金额:4,937,543.50 美元(不变)
  • 批准号:
    10931782
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
MOMS STUDY IMPLEMENTATION (CTN-0080). DSC6. 08/15/2023 - 04/30/2026. N01DA-22-2253. TASK ORDER 75N95023F00006 (TO10).
MOMS 研究实施 (CTN-0080)。
  • 批准号:
    10939540
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
PEER RECOVERY SUPPORT: A BRIDGE TO TREATMENT FOR OVERDOSE SURVIVORS (CTN-0107). 08/15/2023 - 09/14/2024. N01DA-22-2253. TASK ORDER 75N95023F00008 (TO12).
同伴康复支持:药物过量幸存者治疗的桥梁 (CTN-0107)。
  • 批准号:
    10939543
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
DSC MANAGEMENT AND SUPPORT FOR HELPING TO END ADDICTION LONG-TERM INITIATIVE (HEAL). 08/02/2023 - 08/01/2024. N01DA-22-2253. TASK ORDER 75N95023F00009 (TO13).
DSC 管理和支持帮助戒除成瘾长期计划(治愈)。
  • 批准号:
    10939542
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
NIH NATIONAL BRAIN AND TISSUE REPOSITORYPERIOD OF PERFORMANCE: 09/01/2019 - 08/31/2021 (UNCHANGED)TOTAL CONTRACT AMOUNT: $4,937,543.50 (UNCHANGED)T
NIH 国家脑和组织存储库履约期限:2019 年 1 月 9 日 - 2021 年 8 月 31 日(不变)合同总金额:4,937,543.50 美元(不变)T
  • 批准号:
    10910955
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
PRODUCTION OF CANNABIS AND RELATED MATERIALS FOR RESEARCH. 09/01/23 - 08/31/24.
大麻及相关研究材料的生产。
  • 批准号:
    10937563
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
PHASE I COCAINE DRUG INTERACTION STUDY. TO6. NIDA PHARMACOKINETIC ANALYSIS RESOURCE CENTER. 08/10/2023 - 02/09/2025. NIDA REF. NO. N01DA-19-8947.
第一阶段可卡因药物相互作用研究。
  • 批准号:
    10937276
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
NIH NATIONAL BRAIN AND TISSUE REPOSITORYPERIOD OF PERFORMANCE: 09/01/2019 - 08/31/2021 (UNCHANGED)TOTAL CONTRACT AMOUNT: $4,937,543.50 (UNCHANGED)TOTAL OBLIGATED AMOUNT: $4,937,543.50 (UNCHANGED)
NIH 国家脑和组织存储库执行期限:2019 年 1 月 9 日 - 2021 年 8 月 31 日(不变)合同总金额:4,937,543.50 美元(不变)总承付金额:4,937,543.50 美元(不变)
  • 批准号:
    10937264
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
TO AWARD THE BASE PERIOD FOR NIMH PSYCHOACTIVE DRUG SCREENING PROGRAM (PDSP). BASE POP: 08/30/2023-08/29/2024.
授予 NIMH 精神活性药物筛查计划 (PDSP) 基期。
  • 批准号:
    10931140
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
EMERGENCY DEPARTMENT-INITIATED BUPRENORPHINE AND VALIDATION NETWORK TRIAL (CTN-0099). 08/15/2023 - 10/18/2024. N01DA-22-2253. TASK ORDER 75N95023F00007 (TO11).
急诊科发起的丁丙诺啡和验证网络试验 (CTN-0099)。
  • 批准号:
    10939541
  • 财政年份:
    2023
  • 资助金额:
    $ 13.68万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了